FDA Approves Unknown Drug — LANNETT CO INC
On September 25, 2017, Lannett Company received FDA approval for a generic drug indicated by ANDA207333, positioning the company for potential market capture despite unspecified substance details. This clearance allows Lannett to diversify its revenue base, adding another entry to its portfolio as the company continues to target specific niches within a competitive pricing landscape.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day